Sumitomo Dainippon Pharma Co., Ltd. / Cynapsus Therapeutics Inc.

Parkinson's Disease — OFF Episodes

90K US cases/yr · $2.0B Worldwide peak sales potential for APL-130277 (BMO Capital Markets)

Disease Overview

Parkinson's disease is a progressive neurodegenerative disorder driven by dopaminergic neuron loss in the substantia nigra, producing tremor, rigidity, bradykinesia, and postural instability. Approximately 1.1 million Americans live with PD with ~90,000 new diagnoses annually. As disease advances and oral levodopa response narrows, patients experience unpredictable 'OFF' episodes — periods of returning motor symptoms between doses — that affect roughly 40% of patients daily and create demand for fast-onset, on-demand rescue therapies.

Competitive Landscape

At deal time (Aug 2016), the OFF-episode rescue market was effectively limited to subcutaneous apomorphine (Apokyn, US Worldmeds; injection-related side effects, premedication burden, high cost) and rotating oral therapies. Two oral/inhaled rescue assets were in late-stage development: Acorda's CVT-301 (inhaled levodopa, later Inbrija, FDA approved Dec 2018) and Cynapsus's APL-130277 sublingual apomorphine film with 5-10 minute onset. Sunovion paid $40.50/share — a 120% premium, ~$624M total — to acquire Cynapsus on the basis of Phase 3 CTH-300 readout in Q4 2016 and a planned H1 2017 NDA. BMO Capital Markets analyst Do Kim projected potential worldwide sales of ~$2B and characterized the asset as set to 'redefine the acute therapy market for Parkinson's.' The asset received an FDA Complete Response Letter in 2019 over dosing-related issues but ultimately won approval as Kynmobi in May 2020. Commercial uptake disappointed — Sunovion discontinued Kynmobi in March 2021, citing market dynamics — making the deal a strategic miss despite scientific success.